The expanding clinical application of CDK4- and CDK6-inhibiting drugs in the management of hormone-sensitive breast cancer [1,2,3,4] has raised a great interest in also testing these G1/S cell-cycle blocking agents in other neoplasms [5,6,7], for which the potential clinical benefit is still largely unknown. Here, CDK6 is linked to neoplasm.